Table 3. . PD-L1 expression and response rate.
n | PDL-1+ | PDL-1- | Ref. | |
---|---|---|---|---|
Nivolumab, Topalian et al. | 42 | 9/25 (36%) | 0/17 (0%) | [36] |
Nivolumab, Weber et al. | 44 | 8/12 (67%) | 6/32 (19%) | [39] |
Nivolumab, Grosso et al. | 34 | 7/16 (44%) | 3/18 (17%) | [37] |
MPDL3280A, Hamid et al. | 30 | 4/15 (27%) | 3/15 (20%) | [25] |
Nivolumab/ipilimumab, Callahan et al. | 27 | 4/10 (40%) | 8/17 (47%) | [40] |